Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Using Chitosan-Stabilized, Hyaluronic Acid-Modified Selenium Nanoparticles to Deliver Cd44-Targeted Plk1 Sirnas for Treating Bladder Cancer Publisher Pubmed



Shahidi M1 ; Abazari O1 ; Dayati P2 ; Reza JZ1 ; Modarressi MH3 ; Tofighi D4 ; Haghiralsadat BF5 ; Oroojalian F6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences & Health Services, Yazd, 89151, Iran
  2. 2. Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115, Iran
  3. 3. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, 14176, Iran
  4. 4. Department of Psychology, University of New Mexico, Albuquerque, 87131, NM, United States
  5. 5. Medical Nanotechnology & Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, 89151, Iran
  6. 6. Department of Advanced Technologies, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, 94149, Iran
  7. 7. Natural Products & Medicinal Plants Research Center, North Khorasan University of Medical Sciences Bojnurd, 94149, Iran

Source: Nanomedicine Published:2023


Abstract

Aims: Achieving an effective biocompatible system for siRNAs delivery to the tumor site remains a significant challenge. Materials & methods: Selenium nanoparticles (SeNPs) modified by chitosan (CS) and hyaluronic acid (HA) were fabricated for PLK1 siRNAs (siPLK1) delivery to the bladder cancer cells. The HA-CS-SeNP@siPLK1 efficacy was evaluated using in vitro and in vivo models. Results: HA-CS-SeNP@siPLK1 was selectively internalized into T24 cells through clathrin-mediated endocytosis. Treatment with HA-CS-SeNP@siPLK1 successfully silenced the PLK1 gene, inhibited cell proliferation and induced cell cycle arrest in vitro. HA-CS-SeNP@siPLK1 could also inhibit tumor growth in vivo without causing systemic toxicity. Conclusion: Our results suggest that HA-CS-SeNPs may provide a good vehicle for delivering siPLK1 to the bladder tumor site. Plain language summary siRNAs are small biomolecules shown as novel insights in cancer gene therapy because of their capability to silence target genes. However, achieving an effective biocompatible system for siRNA delivery to the tumor site remains a significant challenge. This work aimed to develop a nanoparticle-based delivery system consisting of selenium nanoparticles modified by chitosan and hyaluronic acid to sustain the release of siRNAs to bladder cancer cells. The results of this study demonstrated that this nanosystem successfully silenced the PLK1 gene and reduced the proliferation in vitro and in vivo. These findings suggest that hyaluronic acid-chitosan-selenium nanoparticles may open a new insight for targeted gene therapy for bladder cancer. © 2023 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Hb5 Aptamer-Tagged Graphene Oxide for Co-Delivery of Doxorubicin and Silibinin, and Highly Effective Combination Therapy in Breast Cancer, Cancer Nanotechnology (2023)
2. Enhanced Sirna Delivery and Selective Apoptosis Induction in H1299 Cancer Cells by Layer-By-Layer-Assembled Se Nanocomplexes: Toward More Efficient Cancer Therapy, Frontiers in Molecular Biosciences (2021)
3. Ginger’S Antiapoptotic and Antioxidant Effects on Ovaries of Cyclophosphamide-Therapied Rats, Current Pharmaceutical Design (2023)
4. Aptamer-Functionalized Chitosan-Coated Gold Nanoparticle Complex As a Suitable Targeted Drug Carrier for Improved Breast Cancer Treatment, Nanotechnology Reviews (2022)
5. Silymarin Reduces Retinal Microvascular Damage in Streptozotocin-Induced Diabetic Rats, Scientific Reports (2022)
6. Peptide-Functionalized Polymeric Nanoparticles for Delivery of Curcumin to Cancer Cells, Journal of Drug Delivery Science and Technology (2024)
7. Cd133-Functionalized Gold Nanoparticles As a Carrier Platform for Telaglenastat (Cb-839) Against Tumor Stem Cells, International Journal of Molecular Sciences (2022)
8. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
Experts (# of related papers)
View all Related Experts
Rassoul Dinarvand (2)
Saba Faraji (1)
Other Related Docs
9. Integrated Pan-Cancer of Aurka Expression and Drug Sensitivity Analysis Reveals Increased Expression of Aurka Is Responsible for Drug Resistance, Cancer Medicine (2021)
10. Recent Advances in Regenerative Medicine Strategies for Cancer Treatment, Biomedicine and Pharmacotherapy (2021)
11. Anderson-Type Manganese Polyoxomolybdate Hybrid Nanocomposite for Boosting Drug Delivery Against Breast Cancer, Journal of Drug Delivery Science and Technology (2023)
12. Functions, Mechanisms, and Clinical Applications of Lncrna Linc00857 in Cancer Pathogenesis, Human Cell (2023)
13. Intravesical Gemcitabine Versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial, Urology Journal (2023)
14. Silk-Based Biopolymers Promise Extensive Biomedical Applications in Tissue Engineering, Drug Delivery, and Biomems, Journal of Polymers and the Environment (2023)
15. Switchable Pamam Megamers for Deep Tumor Penetration and Enhanced Cell Uptake, Journal of Controlled Release (2024)
16. Overcoming Multidrug Resistance Through Targeting Abc Transporters: Lessons for Drug Discovery, Expert Opinion on Drug Discovery (2022)
17. Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy, Journal of Nanobiotechnology (2023)
18. Combining Nanotechnology and Gas Plasma As an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication, Oxidative Medicine and Cellular Longevity (2021)
19. Enhancing Sirna Cancer Therapy: Multifaceted Strategies With Lipid and Polymer-Based Carrier Systems, International Journal of Pharmaceutics (2024)